首页工具

Teriparatide

产品编号 T13128 CAS 52232-67-4

别名: 特立帕肽, Human parathyroid hormone-(1-34), hPTH (1-34), PTH 1-34

Teriparatide is an agonist of PHT(IC50 of 2 nM in HEK293 cells). 在相同实验条件下，摩尔浓度相同的化合物盐形式与游离态具有相同的生物活性，但盐形式 Teriparatide acetate 的水溶性和稳定性通常比游离态更好。

TargetMol的所有产品和服务仅用于科学研究，不能被用于人体，我们也不向个人提供产品和服务。

Teriparatide, CAS 52232-67-4

规格	价格/CNY		货期	数量
1 mg	￥ 7,800		35日内发货

大包装超大折扣，点击咨询

Teriparatide 的其他形式现货产品:

Teriparatide acetate

其他形式的 Teriparatide:

Teriparatide acetate
现货

更多批次查询请联系客服

生物活性

化学信息

存储 & 溶解度

参考文献

产品描述	Teriparatide is an agonist of PHT(IC50 of 2 nM in HEK293 cells).
靶点活性	PTH:2 nM
体内活性	In Teriparatide-treated animals, Trabecular bone calcium and dry weight of the distal femur increased significantly. The increase in trabecular calcium compared with vehicle control occurred as early as 1 week after initiation of treatment with a 35% and 45% increase, respectively, for 10 μg/kg and 40 μg/kg Teriparatide. Similar results were observed for trabecular dry weight. After 4 weeks of treatment with 10 mg/kg or 40 mg/kg Teriparatide, trabecular calcium increased significantly by 70% and 123%, respectively, compared with the vehicle and by 73%. The 4-week Teriparatide administration + 8-week vehicle administration decrease the pore ratio, number, and density as well as the cortical area and thickness, compared with the 4-week Teriparatide administration, but the pore ratio, cortical area, and thickness are still higher compared with the 12-week vehicle administration. The 4-week Teriparatide administration increase the pore ratio, number, and density as well as the cortical area, thickness, and bone mineral content (BMC), without significant influencing the volumetric bone mineral density (BMD). The 4-week Teriparatide administration + 8-week higherdose IBN administration increase the cortical area, thickness, BMC, and volumetric BMD and decrease the pore ratio, but not the pore number or density, compared with the 4-week Teriparatide administration + 8-week vehicle administration.

别名	特立帕肽, Human parathyroid hormone-(1-34), hPTH (1-34), PTH 1-34
分子量	4117.72
分子式	C181H291N55O51S2
CAS No.	52232-67-4

存储

keep away from moisture　|　Powder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度

H2O: 50 mg/mL (12.14 mM)

溶液配制表

可选溶剂	浓度体积质量	1 mg	5 mg	10 mg	25 mg
H2O	1 mM	0.2429 mL	1.2143 mL	2.4285 mL	6.0713 mL
	5 mM	0.0486 mL	0.2429 mL	0.4857 mL	1.2143 mL
	10 mM	0.0243 mL	0.1214 mL	0.2429 mL	0.6071 mL

计算器

摩尔浓度计算器

稀释计算器

配液计算器

分子量计算器

质量

浓度

容积

分子量

浓度 (起始)

容积 (起始)

浓度 (终)

容积 (终)

溶液体积

质量

配液浓度

参考文献

1. Iwamoto J, et al. Influence of Teriparatide and Ibandronate on Cortical Bone in New Zealand White Rabbits: A HR-QCT Study. Calcif Tissue Int. 2016 Nov;99(5):535-542.

剂量换算

对于不同动物的给药剂量换算，您也可以参考 更多...

体内实验配液计算器

请在以下方框中输入您的动物实验信息后点击计算，可以得到母液配置方法和体内配方的制备方法：比如您的给药剂量是10 mg/kg，每只动物体重20 g，给药体积100 μL，一共给药动物10 只，您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。

母液配置方法：2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL)，如您需要配置的浓度超过该产品的溶解度，请先与我们联系。

体内配方的制备方法：取 50 μL DMSO 主液，加入 300 μL PEG300，混匀澄清，再加 50 μL Tween 80，混匀澄清，再加 600 μL ddH2O, 混匀澄清。

第一步：请输入动物实验的基本信息

剂量

mg/kg

每只动物体重

给药体积

μL

动物数量

第二步：请输入动物体内配方组成，不同的产品配方组成不同，如有配方需求，可先联系我们提供正确的体内配方。

% DMSO+

% +